Category: Assay Development and Screening
Under physiological conditions, skeletal muscle is the predominant site of glucose disposal and fuel utilization in humans. Skeletal muscle insulin resistance is the primary defect in the pathogenesis of type 2 diabetes. However, currently there is no anti-diabetic medications directly targeting insulin resistance in skeletal muscle.
Ectopic lipid accumulation has been proposed as the underlying pathogenesis of insulin resistance. Although insulin resistance can occur independently of intramyocellular lipid (IMCL) level, IMCL content has been considered as a predictor of muscle insulin resistance, and lipid metabolites (diglyceride (DAG) and ceramides) have been shown to directly impair insulin signaling.
Yi Yang– Sr. Scientist, Merck & Co., Boston, MA
Merck & Co.
Yi Yang has been working at Merck & Co. since 2000. She has extensive knowledge in cell biology, molecular biology and protein biochemistry. She is a Senior Scientist in Cell Pharmacology group at Merck Boston, focusing on cell culture and cell-based screen since 2011. From 2004 to 2011, she worked in Investigative Toxicology department on drug induced toxicity and biomarker identification. From 2000 to 2004, she worked in Cancer Research department focusing on cell-based screens for cell cycle, checkpoint and cell survival Oncology. Prior to joining Merck, Yi Yang worked on protein chemistry at Abramson research center in The Children’s hospital of Philadelphia. Yi Yang got her MS from West China Medical School, Sichuan University, and received advanced training in molecular biology and immunology from Kyushu University, Japan.